41.69

2.33% 0.95

Pre-market: 41.80 0.11 +0.26%

Exelixis Inc (EXEL)

Overview News Price History Option Chain Financials Why EXEL Down? Discussions Forecast

Exelixis Inc stock is traded at $41.69, with a volume of 4.21M. It is up +2.33% in the last 24 hours and down -2.25% over the past month. Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Previous Close:

$40.74

Open:

$41.06

24h Volume:

4.21M

Relative Volume:

1.56

Market Cap:

$10.83B

Revenue:

$2.29B

Net Income/Loss:

$677.90M

P/E Ratio:

17.55

EPS:

2.3753

Net Cash Flow:

$779.77M

1W Performance:

-6.84%

1M Performance:

-2.25%

6M Performance:

+11.53%

1Y Performance:

+8.88%

1-Day Range:

$40.69

$41.83

1-Week Range:

$39.71

$45.01

52-Week Range:

$32.38

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Name

Exelixis Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(650) 837-7000

Address

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Employee

1,077

Twitter

@exelixisinc

Next Earnings Date

2025-07-28

Latest SEC Filings

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXEL Exelixis Inc	41.69	10.58B	2.29B	677.90M	779.77M	2.3753
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-05-26	Downgrade	BofA Securities	Neutral → Underperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-21-25	Upgrade	Leerink Partners	Market Perform → Outperform
Sep-19-25	Resumed	Barclays	Equal Weight
Sep-17-25	Resumed	Barclays	Equal Weight
Sep-17-25	Initiated	Goldman	Buy
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jun-24-25	Upgrade	Stephens	Equal-Weight → Overweight
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform
Sep-19-24	Initiated	UBS	Neutral
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-23	Initiated	BTIG Research	Buy
Dec-15-23	Initiated	Citigroup	Buy
Sep-26-23	Initiated	H.C. Wainwright	Buy
Aug-22-23	Reiterated	Oppenheimer	Outperform
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight
May-10-23	Resumed	Piper Sandler	Overweight
Mar-09-23	Initiated	Wells Fargo	Overweight
Jan-26-23	Initiated	Credit Suisse	Outperform
Oct-18-22	Initiated	JMP Securities	Mkt Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Nov-19-21	Initiated	Piper Sandler	Overweight
Nov-03-21	Resumed	Jefferies	Buy
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Reiterated	H.C. Wainwright	Buy
Jun-15-21	Initiated	H.C. Wainwright	Buy
May-18-21	Resumed	Goldman	Sell
Mar-31-21	Initiated	Credit Suisse	Outperform
Mar-12-21	Initiated	Wolfe Research	Outperform
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Initiated	SunTrust	Buy
Nov-13-19	Initiated	BofA/Merrill	Buy
Mar-18-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-17-18	Initiated	Goldman	Neutral
Sep-10-18	Initiated	Morgan Stanley	Underweight
May-11-18	Reiterated	Needham	Buy
Oct-17-17	Reiterated	Needham	Buy
Oct-17-17	Reiterated	RBC Capital Mkts	Outperform
Oct-16-17	Reiterated	SunTrust	Buy
Sep-22-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-12-17	Reiterated	Needham	Buy
Jul-14-17	Initiated	SunTrust	Buy
Mar-31-17	Initiated	Needham	Buy
Mar-16-17	Initiated	Oppenheimer	Perform
Feb-28-17	Downgrade	Stifel	Buy → Hold
Nov-03-16	Initiated	Deutsche Bank	Buy
Oct-10-16	Upgrade	Piper Jaffray	Neutral → Overweight
Sep-15-16	Reiterated	Stifel	Buy

View All

Exelixis Inc Stock (EXEL) Latest News

Mar 04, 2026

A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st

Mar 04, 2026

Mar 03, 2026

EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView

Mar 03, 2026

Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm

Mar 03, 2026

Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st

Mar 03, 2026

Mar 02, 2026

Exelixis (EXEL) EVP Haley granted 40,459 RSUs vesting from 2027 - Stock Titan

Mar 02, 2026

Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan

Mar 02, 2026

Exelixis stock falls after rival Merck trial shows better results - Investing.com

Mar 02, 2026

RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus

Mar 02, 2026

Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat

Mar 02, 2026

Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget

Mar 02, 2026

Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat

Mar 02, 2026

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

Mar 02, 2026

RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com

Mar 02, 2026